Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNOVATION trial of trastuzumab with or without pertuzumab added to perioperative chemotherapy in HER2-positive resectable gastric or gastroesophageal junction cancer
NL-OMON53087Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab and pertuzumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Major pathological response rate. Started Jul 2020; status: completed.
02
Drugs
trastuzumabpertuzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON53087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53087.